


## Synthesis of *N*-Oxyamide-Linked Neoglycolipids

Na Chen and Juan Xie\*

PPSM, ENS Cachan, CNRS UMR 8531, 61 av President Wilson, F-94230 Cachan, France


**S** Supporting Information



**ABSTRACT:** *N*-Oxyamide-containing compounds have shown improved metabolic stability and interesting secondary structures due to the good hydrogen bond-donating property of *N*-oxyamide.  $\beta$ -Glucolipids linked by the *N*-oxyamide bond have been successfully synthesized as novel mimics of glyco glycerolipids and glycosphingolipids.

As part of the glycoconjugate family, glycolipids are implicated in a variety of important biological phenomena such as cell–cell interactions, viral and bacterial infections, immune response, signal transduction, cell proliferation, etc. Glycolipids are composed of one or several monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety like an acylglycerol (termed glyco glycerolipids, GGLs) or a ceramide (glycosphingolipids, GSLs). GGLs and mammalian GSLs begin with either glucose or galactose attached in  $\alpha$ - or  $\beta$ -linkage to the 1-hydroxyl of mono/diacylglycerol or ceramide. Ceramides consist of fatty-amide-linked sphingosine (a long-chain amino alcohol). GGLs mainly exist in plants, algae, and bacteria. They have shown interesting anti-tumor-promoting activities.<sup>1</sup> Inhibitory effects on DNA polymerase, human Myt1-kinase, human lanosterol synthase, and antitumor activities have also been reported.<sup>2</sup> Bacterial glyco glycerolipid BbGL2 has been shown to induce natural killer T cell (NKT cell) proliferation and cytokine production,<sup>3</sup> an important property known for GSL agelashins.<sup>4</sup> As a most abundant and diverse class of glycolipids in animals, GSLs are found in the plasma membrane of cells and play key roles in cell–cell interactions and protein activities.<sup>5</sup> As immunostimulating agents,<sup>6</sup> these glycolipids have attracted intensive research interest, in particular, since the discovery of a potent NKT immune cell activation effect of synthetic  $\alpha$ -galactosyl ceramide ( $\alpha$ -GalCer or KRN7000).<sup>7</sup> The design of glycolipid mimics has become a useful strategy in drug discovery. Modifications have been made on the sugar part, on the configuration and nature of the anomeric bond (*C*-, *S*-glycoside), on the polar moiety of the ceramide or glycerol, or on the lipid chains.<sup>7</sup> Triazole-containing glycolipids have also been reported, showing a comparable stimulatory effect on cytokine production as  $\alpha$ -GalCer.<sup>8</sup> The ability to undergo extensive interlipid hydrogen bonding has been considered to be fundamental for the functions of glycolipids in membranes, through imparting structural integrity to the membranes of the organisms.<sup>9</sup> *N*-Oxyamide bonds in peptide<sup>10</sup> and sugar derivatives<sup>11</sup> have been found to be good hydrogen-bond-donating groups due to lone pair repulsion between adjacent nitrogen and oxygen. They can

easily organize into turns and helices through intramolecular hydrogen bond formation. This unique property makes *N*-oxyamide linkage attractive for the modification of biomolecules. Furthermore, *N*-oxypeptides are resistant to chemical and enzymatic hydrolysis.<sup>12</sup> With a continuing interest in *N*-oxyamide-containing biomolecules,<sup>13</sup> we designed the *N*-oxyamide-linked glycolipids, by replacing the ester function in GGLs by a *N*-oxyamide (Figure 1). These kinds of glycolipids,





**Figure 1.** Structure of GGLs, GSLs, and *N*-oxyamide-linked glycolipids.

never reported in the literature, could be considered as analogues of both GGL and GSL (Figure 1). Only one *N*(OMe)-glycoceramide has very recently been reported showing potent inhibitory activity against recombinant endoglycoceramidase II.<sup>14</sup> Because the  $\beta$ -linked glucose unit widely exists in natural glycolipids, we investigated first the synthesis of *O*-amino  $\beta$ -glucoglycerol and its application to *N*-oxyamide-containing glycolipids.

The synthetic strategy toward *N*-oxyamide-containing glycolipids would be the stereoselective synthesis of *O*-amino  $\beta$ -glucoglycerol **10** through Mitsunobu reaction on glycosylglycerol **7**, which can be obtained via glycosylation with

**Received:** September 16, 2014


**Published:** October 15, 2014

Scheme 1. Retrosynthesis of *N*-Oxyamide-Linked GlycolipidsScheme 2. Preparation of 1,2-Di-*O*-benzyl-*sn*-glycerol 5

dibenzylated glycerol **5**, followed by introduction of lipid chains and final deprotection (Scheme 1).

The required glycerol **5**<sup>15</sup> was prepared in 64% overall yield from D-(+)-mannitol, as outlined in Scheme 2. It is important to control the reaction conditions to convert triacetate **1** to 3,4-isopropylidene-D-mannitol **2**.<sup>15</sup> Deprotection with 70% AcOH at 40 °C<sup>15</sup> gave 50% yield of **2**. The best result (80%) was obtained using 30% AcOH<sup>17</sup> at 40 °C during 1 h.

Glycosylation of glycerol **5** was realized with per-*O*-acetyl- $\alpha$ -D-glucopyranosyl bromide generated from D-glucose pentaacetate (Scheme 3). Dropwise addition of glycosyl bromide in dry acetonitrile into the solution containing compound **5**, HgBr<sub>2</sub>, and Hg(CN)<sub>2</sub> is crucial to prepare  $\beta$ -glucoglycerol **6**<sup>15</sup> in good yield (75% for two steps). After debenzylation, regioselective silylation of **7**<sup>18</sup> required the presence of *N*-methylimidazole and iodine<sup>19</sup> as promoter to ensure good reactivity and regioselectivity. The oxyamine function was then introduced via Mitsunobu reaction with PhthNOH to afford compound **9** with inversion of configuration.<sup>20</sup> Removal of the TBS group was achieved with catalytic AcCl in MeOH in 72% yield, instead of TBAF which deprotected acetyl groups, leading to a mixture of products.

Scheme 3. Synthesis of *O*-Amino  $\beta$ -Glucoglycerol **10**


Next, esterification of the *O*-phthaloylamino  $\beta$ -glucoglycerol **10** with palmitic acid using 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) furnished the glucolipid **11** in excellent yield (98%) (Scheme 4). Hydrazinolysis under mild conditions (1.1 equiv, 20 min at 0 °C) deprotected selectively the phthaloyl group. Coupling of the resulting oxyamine **12** with different fatty acids led successfully to the neoglycolipids **13–17** in 64–87% yield. The NH of the *N*-oxyamide bond appeared between 8.81 and 8.87 ppm on the <sup>1</sup>H NMR in CDCl<sub>3</sub>. Final deacetylation was realized with hydrazine at 50 °C in EtOH to give the target compounds **18–22**. Due to their amphiphilic nature, some glycolipids are lost during the workup, leading to low yields (34–61%).

In conclusion, we have achieved the first synthesis of *N*-oxyamide-linked  $\beta$ -glucolipids from readily available D-glucose penta-acetate and D-mannitol via the *O*-amino  $\beta$ -glucoglycerol **10** as a versatile intermediate. Different lipid chains could be easily introduced on hydroxyl and oxyamine functions to access a variety of glycolipid structures. Synthesis of 1,2-di-*O*-benzyl-*sn*-glycerol **5** has also been optimized.

## EXPERIMENTAL SECTION

**3,4-*O*-Isopropylidene-D-mannitol (2).** To a stirred solution of 30% aq AcOH (200 mL) was added D-mannitol triacetate **1** (10 g, 33.1 mmol). The mixture was stirred at 40 °C. After 1 h, the solution was evaporated and residual AcOH removed by repeated coevaporation with toluene. Dry acetone was added, and the mixture was thoroughly stirred with excess anhyd K<sub>2</sub>CO<sub>3</sub> and then filtered. The insoluble material (remaining mannitol) was washed with acetone, and the combined filtrates were evaporated. The residue was then dissolved in a small volume of EtOAc and allowed to crystallize at rt to give pure product (5.89 g, 80.1%): *R*<sub>f</sub> = 0.43 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 10/1); <sup>1</sup>H NMR (400 MHz, acetone-*d*<sub>6</sub>)  $\delta$  4.73 (s, 2H, 2  $\times$  OH), 3.96–3.90 (m, 2H, 2  $\times$  CH), 3.77–3.54 (m, 8H, 2  $\times$  CH, 2  $\times$  CH<sub>2</sub>, 2  $\times$  OH), 1.32 (s, 6H, 2  $\times$  CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, acetone-*d*<sub>6</sub>)  $\delta$  109.8 (C<sub>q</sub>), 80.8, 74.2 (CH); 64.6 (CH<sub>2</sub>), 27.3 (CH<sub>3</sub>).

**1,2,5,6-Tetra-*O*-benzyl-3,4-*O*-isopropylidene-D-mannitol (3).** NaH (60%, 6.36 g, 159 mmol) was added to a stirred solution of **2** (5.88 g, 26.49 mmol) in dry DMF (200 mL). The suspension was stirred for 0.5 h at 0 °C in an ice bath. BnBr (15.11 mL, 127 mmol) was then added, and the stirring continued at rt overnight. Ice was added to destroy the excess NaH, and the solution was then concentrated, diluted with saturated aq NH<sub>4</sub>Cl, and the product extracted with EtOAc (200 mL). The extract was washed with water and brine, dried over MgSO<sub>4</sub>, and evaporated. Purification by column chromatography (petroleum ether/EtOAc 15/1) afforded compound **3** as a colorless syrup (15.10 g, 98%): *R*<sub>f</sub> = 0.31 (petroleum ether/EtOAc 10/1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.41–7.17 (m, 20H, H-Ph), 4.73 (d, *J* = 11.8 Hz, 2H, 2  $\times$  CH), 4.57 (d, *J* = 11.7 Hz, 2H, 2  $\times$  CH), 4.48–4.46 (m, 4H, 2  $\times$  CH<sub>2</sub>), 4.24–4.15 (m, 2H, 2  $\times$  CH), 3.81–3.55 (m, 6H, 2  $\times$  CH<sub>2</sub>, 2  $\times$  CH), 1.35 (s, 6H, 2  $\times$  CH<sub>3</sub>); <sup>13</sup>C

Scheme 4. Synthesis of *N*-Oxamide-Linked Neoglycolipids

NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  138.6, 138.5 ( $\text{C}_q$ ); 128.5, 128.4, 128.0, 127.7, 127.6 (CH-Ph); 109.9 ( $\text{C}_q$ ); 79.4, 78.6 (CH); 73.4, 72.9, 70.7 ( $\text{CH}_2$ ); 27.3 ( $\text{CH}_3$ ).

**1,2,5,6-Tetra-O-benzyl-D-mannitol (4).** Compound 3 (15.10 g, 25.96 mmol) was treated with 1 M aq HCl/MeOH (1:9, v/v, 250 mL) under reflux for 4 h, when TLC showed a new single spot. Excess solid  $\text{NaHCO}_3$  was added, and the solution evaporated to give an oil which was dissolved in EtOAc (300 mL), dried over  $\text{MgSO}_4$ , and evaporated. Purification by column chromatography (petroleum ether/EtOAc 5/1) afforded compound 4 (13.08 g, 93%) as a colorless syrup:  $R_f$  = 0.12 (petroleum ether/EtOAc 5/1);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34–7.26 (m, 20H, H-Ph), 4.72 (d,  $J$  = 11.5 Hz, 2H, 2  $\times$  CH), 4.59 (d,  $J$  = 11.5 Hz, 2H, 2  $\times$  CH), 4.54 (s, 4H, 2  $\times$   $\text{CH}_2$ ), 3.96 (m, 2H, 2  $\times$  CH), 3.80–3.65 (m, 6H, 2  $\times$   $\text{CH}_2$ , 2  $\times$  CH), 3.04 (s, 1H, OH), 3.02 (s, 1H, OH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  138.3, 138.1 ( $\text{C}_q$ ); 128.5, 128.1, 127.9, 127.8 (CH-Ph); 79.3 (CH); 73.6, 73.2, 70.3 ( $\text{CH}_2$ ); 70.1 (CH).

**1,2-Di-O-benzyl-*sn*-glycerol (5).** To a solution of 4 (14.10 g, 26 mmol) in MeOH (250 mL) was added an aq solution of  $\text{NaO}_4$  (8.56 g, 40 mmol in 150 mL of water). The reaction mixture was stirred for 3 h at rt, after which time TLC analysis revealed the oxidation to be complete ( $R_f$  = 0.52, petroleum ether/EtOAc 3/1). The reaction mixture was diluted with MeOH (200 mL) and cooled. The precipitate was filtered off, and to the filtrate was added  $\text{NaBH}_4$  (9.84 g, 260 mmol). After 1 h, the reaction mixture was treated with AcOH, and the solution evaporated to a small volume which was diluted in  $\text{CH}_2\text{Cl}_2$  (300 mL), dried over  $\text{MgSO}_4$ , and concentrated. Purification by column chromatography (petroleum ether/EtOAc 3/1) afforded compound 5 (13.87 g, 98%) as a colorless syrup:  $R_f$  = 0.24 (petroleum ether/EtOAc 3/1);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.38–7.26 (m, 10H, H-Ph), 4.74–4.53 (m, 4H, 2  $\times$   $\text{CH}_2$ ), 3.79–3.57 (m, 5H, 2  $\times$  CH, CH), 2.05 (s, 1H, OH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  138.4, 138.1 ( $\text{C}_q$ ); 128.6, 128.6, 128.0, 127.9, 127.8 (CH-Ph); 78.1 (CH); 73.7, 72.3, 70.3, 63.0 ( $\text{CH}_2$ ).

**(2R)-1,2-Di-O-benzyl-3-O-(2',3',4',6'-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)glycerol (6).** To a solution of  $\alpha$ -D-glucose pentaacetate (2 g, 5.12 mmol) in  $\text{CH}_2\text{Cl}_2$  (15 mL) was added HBr (33% in AcOH, 7 mL, 41 mmol) at 0 °C. The mixture was stirred at rt under Ar for 6 h, and then the solution was neutralized with aq  $\text{NaHCO}_3$ . The resulting 2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide was extracted with  $\text{CH}_2\text{Cl}_2$  (100 mL), dried over  $\text{MgSO}_4$ , and evaporated to give a syrup. To a solution of 1,2-di-O-benzyl-*sn*-glycerol (5) (1.41 g, 5.2 mmol),  $\text{HgBr}_2$  (0.94 g, 2.6 mmol), and  $\text{Hg}(\text{CN})_2$  (0.66 g, 2.6 mmol) in dry MeCN (20 mL) was added dropwise over a period of 1 h a solution of glycosyl bromide in MeCN (10 mL). The reaction solution was stirred at rt overnight and then concentrated to an oil which was dissolved in  $\text{CH}_2\text{Cl}_2$  (100 mL) and washed with saturated aq KBr (2  $\times$  30 mL) and water (30 mL). The dried ( $\text{MgSO}_4$ ) organic layer was concentrated. Purification by column chromatography (petroleum ether/EtOAc 3/1) afforded compound 6 (2.30 g, 75%) as a colorless paste:  $R_f$  = 0.39 (petroleum ether/EtOAc 2/1);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.37–7.28 (m, 10H, H-Ph), 5.18 (t,  $J$  = 9.4 Hz, 1H, H-3'), 5.09 (t,  $J$  = 9.7 Hz, 1H, H-4'), 5.00 (dd,  $J$  = 9.5, 8.2 Hz, 1H, H-2'), 4.65 (s, 2H,  $\text{CH}_2$ ), 4.57–4.50 (m, 3H, H-1',  $\text{CH}_2$ ), 4.28–4.09

(m, 2H, H-6'), 3.99–3.69 (m, 3H, H-2,3), 3.65 (ddd,  $J$  = 10.0, 4.5, 2.3 Hz, 1H, H-5'), 3.59–3.57 (m, 2H, H-1), 2.07, 2.04, 2.03, 2.01 (4  $\times$  s, 12H, 4  $\times$  OAc);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.9, 170.5, 169.6, 169.5 (C=O); 138.5, 138.3 ( $\text{C}_q$ ); 128.6, 128.5 (CH-Ph); 101.2 (C-1'), 76.8 (CH), 73.6 ( $\text{CH}_2$ ), 72.9 (C-3'), 72.3 ( $\text{CH}_2$ ), 71.9 (C-5'), 71.4 (C-2'), 69.8, 69.4 ( $\text{CH}_2$ ); 68.5 (C-4'), 62.0 (C-6'), 20.9, 20.8 (OAc).

**(2R)-1-O-(2',3',4',6'-Tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-glycerol (7).** A mixture of 6 (12 g, 20 mmol) and 10% Pd/C (1.8 g) in EtOAc (100 mL) containing 5 mL each of EtOH and AcOH was vigorously shaken under  $\text{H}_2$  at rt overnight. The catalyst was filtered off, and the filtrate evaporated. Purification by column chromatography ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  25/1) afforded compound 7 (6 g, 71%) as a white solid:  $R_f$  = 0.12 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  25/1);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  5.22 (t,  $J$  = 9.6 Hz, 1H, H-3'), 5.11–5.04 (m, 1H, H-4'), 5.04–4.97 (m, 1H, H-2'), 4.55 (d,  $J$  = 7.8 Hz, 1H, H-1'), 4.25–4.16 (m, 2H, H-6'), 3.89–3.79 (m, 3H, H-2,3), 3.77–3.57 (m, 3H, H-1,5'), 2.32 (s, 2H, 2  $\times$  OH), 2.11, 2.07, 2.04, 2.01 (4  $\times$  s, 12H, 4  $\times$  OAc);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.8, 170.3, 169.7, 169.5 (C=O); 101.4 (C-1'), 72.6 (C-3'), 72.0 (C-5'), 71.3 (C-2'), 70.5 (CH), 68.4 (C-4'), 63.4, 61.9 ( $\text{CH}_2$ ); 20.8, 20.7 (OAc).

**1-O-*tert*-Butyldimethylsilyl-3-O-(2',3',4',6'-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-*sn*-glycerol (8).** To a solution of 7 (2 g, 4.74 mmol), *N*-methylimidazole (1.14 mL, 14.22 mmol), and iodine (3.61 g, 14.22 mmol) in anhyd THF (20 mL) under Ar at 0 °C was added TBSCl (0.86 g, 5.69 mmol). The reaction mixture was stirred for 20 min at 0 °C and then quenched with saturated aq  $\text{Na}_2\text{S}_2\text{O}_3$  and diluted with EtOAc (50 mL). The aqueous layers were extracted with EtOAc (2  $\times$  50 mL). The combined organic layers were dried over  $\text{MgSO}_4$ , filtered, concentrated, and purified by column chromatography over silica gel ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  100/1) to afford 8 (2.43 g, 95.7%) as a yellowish paste:  $R_f$  = 0.74 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  100/3);  $[\alpha]_D^{25}$   $-9.7$  (c 0.1,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  5.20 (dd,  $J$  = 12.0, 6.9 Hz, 1H, H-3'), 5.05 (t,  $J$  = 9.7 Hz, 1H, H-4'), 4.98 (dd,  $J$  = 9.6, 8.1 Hz, 1H, H-2'), 4.54 (d,  $J$  = 7.9 Hz, 1H, H-1'), 4.25–4.11 (m, 2H, H-6'), 3.82–3.68 (m, 4H, H-2,3,5'), 3.62–3.58 (m, 2H, H-1), 2.08, 2.04, 2.01, 1.99 (4  $\times$  s, 12H, 4  $\times$  OAc), 0.88 (s, 9H, *t*-Bu), 0.05 (s, 6H,  $\text{Si}(\text{CH}_3)_2$ );  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.7, 170.3, 169.5, 169.4 (C=O); 101.4 (C-1'), 72.8 (C-3'), 71.9 (C-5'), 71.7 ( $\text{CH}_2$ ), 71.4 (C-2'), 70.5 (CH), 68.5 (C-4'), 63.7, 62.0 ( $\text{CH}_2$ ); 25.9, 20.8, 20.7 ( $\text{CH}_3$ ); 18.3 ( $\text{C}_q$ , *t*-Bu),  $-5.4$  ( $\text{CH}_3$ ,  $\text{Si}(\text{CH}_3)_2$ ); HRMS (ESI)  $m/z$   $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{23}\text{H}_{41}\text{O}_{12}\text{Si}$  537.2367; found 537.2362 (all HRMS spectra were recorded on a Q-TOF MaXis using standard conditions).

**(2R)-2-O-Phthalimido-1-O-*tert*-butyldimethylsilyl-3-O-(2',3',4',6'-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)glycerol (9).** To a solution of 8 (2.10 g, 3.91 mmol) in toluene (60 mL) were added  $\text{Ph}_3\text{P}$  (3.08 g, 11.7 mmol), PhthNOH (1.91 g, 11.7 mmol), and DIAD (2.30 mL, 11.7 mmol) at 0 °C. The resulting mixture was stirred at rt for 2 h under Ar and then extracted with EtOAc (3  $\times$  50 mL). The combined organic layers were washed with brine (50 mL), dried over  $\text{MgSO}_4$ , filtered, evaporated, and purified by column chromatography over silica gel (petroleum ether/EtOAc 3/1) to afford 9 (2.39 g, 90%) as a paste:  $R_f$  = 0.53 (petroleum ether/EtOAc 1/1);  $[\alpha]_D^{25}$   $-13.3$  (c 0.1,

CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83–7.70 (m, 4H, Phth), 5.16 (t, *J* = 9.6 Hz, 1H, H-3'), 5.02 (t, *J* = 9.8 Hz, 1H, H-4'), 4.92 (dd, *J* = 9.4, 8.1 Hz, 1H, H-2'), 4.66 (d, *J* = 7.8 Hz, 1H, H-1'), 4.39–4.41 (m, 1H, H-2), 4.21 (dd, *J* = 12.3, 4.8 Hz, 1H, H-6'a), 4.15–4.06 (m, 2H, H-3a,6'b), 3.93 (dd, *J* = 11.7, 6.2 Hz, 1H, H-3b), 3.89 (d, *J* = 4.7 Hz, 2H, H-1), 3.69 (ddd, *J* = 10.0, 4.7, 2.2 Hz, 1H, H-5'), 2.06, 2.01, 1.99, 1.96 (4 × s, 12H, 4 × OAc), 0.77 (s, 9H, *t*-Bu), –0.02, –0.03 (2 × s, 6H, Si(CH<sub>3</sub>)<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 170.8, 170.4, 169.6, 169.6 (C=O), 163.7 (C=O, Phth); 134.5, 129.0 (C<sub>q</sub>), 123.6 (Phth), 100.8 (C-1'), 87.0 (C-2), 73.0 (C-3'), 71.8 (C-5'), 71.2 (C-2'), 68.4 (C-4'), 68.0, 62.0, 61.9 (CH<sub>2</sub>); 25.8, 20.8, 20.8, 20.7 (CH<sub>3</sub>); 18.2 (C<sub>q</sub>, *t*-Bu), –5.6 (CH<sub>3</sub>, Si(CH<sub>3</sub>)<sub>2</sub>); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>31</sub>H<sub>44</sub>NO<sub>14</sub>Si 682.2531; found 682.2526.

**2-O-Phthalimido-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-sn-glycerol (10).** To a solution of **9** (1.0 g, 1.47 mmol) in MeOH (30 mL) was added AcCl (16 μL, 0.22 mmol) at 0 °C. The resulting mixture was stirred at rt for 2 h under Ar and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by column chromatography over silica gel (petroleum ether/EtOAc 1/1) to give **10** (0.59 g, 72%) as a white powder. mp 72 °C; *R*<sub>f</sub> = 0.23 (petroleum ether/EtOAc 1/1); [α]<sub>D</sub><sup>20</sup> –17.3 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.87–7.74 (m, 4H, Phth), 5.22–5.15 (m, 1H, H-3'), 5.03 (t, *J* = 10.1 Hz, 1H, H-4'), 4.97 (m, 1H, H-2'), 4.64 (d, *J* = 7.8 Hz, 1H, H-1'), 4.32–4.26 (m, 1H, H-2), 4.22 (dd, *J* = 12.3, 4.9 Hz, 1H, H-6'a), 4.14–4.06 (m, 2H, H-3a,6'b), 4.01 (dd, *J* = 11.6, 6.3 Hz, 1H, H-3b), 3.83–3.66 (m, 3H, H-1,5'), 2.07, 2.04, 1.99, 1.97 (4 × s, 12H, 4 × OAc); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 170.8, 170.3, 169.6, 169.5 (C=O), 164.6 (C=O, Phth); 135.0, 128.8 (C<sub>q</sub>); 124.0 (Phth), 100.9 (C-1'), 88.1 (CH), 72.8 (C-3'), 71.9 (C-5'), 71.1 (C-2'), 68.5 (C-4'), 67.8, 61.9, 60.4 (CH<sub>2</sub>); 20.8, 20.7, 20.7 (OAc); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>30</sub>NO<sub>14</sub> 568.1666; found 568.1661.

**(2R)-1-O-Palmitoyl-2-O-phthalimido-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (11).** To a solution of palmitic acid (0.26 g, 1.02 mmol) in anhyd CH<sub>2</sub>Cl<sub>2</sub> (10 mL) were added DMAP (0.25 g, 2.04 mmol), EDC·HCl (0.39 g, 2.04 mmol), and Et<sub>3</sub>N (0.28 mL, 2.04 mmol) under Ar at 0 °C. After the mixture was stirred for 20 min, compound **10** (0.58 g, 1.02 mmol) was added. The resulting mixture was stirred at rt overnight. The solution was diluted with EtOAc (30 mL), washed with aq HCl (1 N, 2 × 15 mL), saturated aq NaHCO<sub>3</sub> (2 × 15 mL), and brine (15 mL), dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by column chromatography over silica gel (petroleum ether/EtOAc 2/1) to afford **11** (1.05 g, 98.6%) as a white solid: mp 65 °C; *R*<sub>f</sub> = 0.54 (petroleum ether/EtOAc 1/1); [α]<sub>D</sub><sup>20</sup> –11.0 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.87–7.74 (m, 4H, Phth), 5.20 (t, *J* = 9.5 Hz, 1H, H-3'), 5.06 (t, *J* = 9.7 Hz, 1H, H-4'), 4.96 (dd, *J* = 9.2, 7.8 Hz, 1H, H-2'), 4.68 (d, *J* = 8.2 Hz, 1H, H-1'), 4.62–4.53 (m, 1H, H-2), 4.44–4.31 (m, 2H, H-3), 4.25 (dd, *J* = 12.3, 4.8 Hz, 1H, H-6'a), 4.18–4.07 (m, 2H, H-1a,6'b), 4.01 (dd, *J* = 11.8, 5.8 Hz, 1H, H-1b), 3.73 (ddd, *J* = 9.9, 4.7, 2.4 Hz, 1H, H-5'), 2.38–2.24 (m, 2H, CH<sub>2</sub>), 2.10, 2.05, 2.02, 1.99 (4 × s, 12H, 4 × OAc), 1.65–1.52 (m, 2H, CH<sub>2</sub>), 1.35–1.20 (m, 24H, 12 × CH<sub>2</sub>), 0.88 (t, *J* = 6.9 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.5, 170.8, 170.4, 169.6, 169.5, 163.6 (C=O); 134.8, 128.9 (C<sub>q</sub>); 123.8 (CH), 100.9 (C-1'), 84.5 (CH), 72.9 (C-3'), 72.0 (C-5'), 71.1 (C-2'), 68.5 (C-4'), 67.8, 62.4, 62.0, 34.1, 32.1, 29.8, 29.8, 29.6, 29.5, 29.4, 29.3, 24.9, 22.8 (CH<sub>2</sub>); 20.9, 20.8, 20.7, 14.3 (CH<sub>3</sub>); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>60</sub>NO<sub>15</sub> 806.3963; found 806.3957.

**(2R)-2-O-Amino-1-O-palmitoyl-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (12).** To a solution of **11** (0.38 g, 0.47 mmol) in MeOH (3 mL) was added N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (25.2 μL, 0.52 mmol) at 0 °C. The resulting mixture was stirred at 0 °C for 20 min under Ar and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by column chromatography over silica gel (petroleum ether/EtOAc 3/2) to afford **12** (0.31 g, 96%) as a paste: *R*<sub>f</sub> = 0.40 (petroleum ether/EtOAc 1/1); [α]<sub>D</sub><sup>20</sup> –46.7 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.22 (t, *J* = 8.7 Hz, 1H, H-3'), 5.06 (t, *J* = 9.6 Hz, 1H, H-4'), 4.96 (dd, *J* = 9.6, 7.8 Hz, 1H, H-2'), 4.57 (d, *J* = 7.8 Hz, 1H, H-1'), 4.39–4.06 (m, 4H, H-3,6'), 4.04–3.90

(m, 2H, H-1a,2), 3.79–3.65 (m, 2H, H-1b,5'), 2.32 (t, *J* = 7.5 Hz, 2H, CH<sub>2</sub>), 2.09, 2.07, 2.03, 2.01 (4 × s, 12H, 4 × OAc), 1.68–1.57 (m, 2H, CH<sub>2</sub>), 1.39–1.20 (m, 24H, 12 × CH<sub>2</sub>), 0.88 (t, *J* = 6.7 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.9, 170.8, 170.4, 169.5 (C=O); 101.2 (C-1'), 80.1 (CH), 72.8 (C-3'), 72.0 (C-5'), 71.3 (C-2'), 68.5 (C-4'), 68.0, 62.0, 61.9, 34.3, 32.1, 29.8, 29.6, 29.5, 29.4, 29.3, 25.1, 22.8 (CH<sub>2</sub>); 20.9, 20.8, 20.7, 14.2 (CH<sub>3</sub>); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>58</sub>NO<sub>13</sub> 676.3908; found 676.3903.

**General Procedure A for N-Oxyamide Formation. Synthesis of (2R)-2-O-Acylamino-1-O-palmitoyl-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (13–17).** To a solution of carboxylic acid (0.25 mmol) in anhyd CH<sub>2</sub>Cl<sub>2</sub> (4 mL) were added HOBt (0.5 mmol), EDC·HCl (0.5 mmol), and Et<sub>3</sub>N (0.5 mmol) under Ar at 0 °C. After being stirred for 20 min, the oxyamine **12** (0.25 mmol) was added. The resulting mixture was stirred at rt overnight. The solution was diluted with EtOAc (25 mL), washed with aq HCl (1 N, 2 × 10 mL), saturated aq NaHCO<sub>3</sub> (2 × 10 mL), and brine (10 mL), dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by column chromatography over silica gel (petroleum ether/EtOAc 2/1).

**(2R)-2-O-Hexanoylamino-1-O-palmitoyl-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (13).** From **12** (153 mg, 0.23 mmol) and hexanoic acid, compound **13** was obtained as a paste (145 mg, 82%); *R*<sub>f</sub> = 0.60 (petroleum ether/EtOAc 1/1); [α]<sub>D</sub><sup>20</sup> –35.7 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.83 (s, 1H, NH), 5.24 (t, *J* = 9.5 Hz, 1H, H-3'), 5.09 (t, *J* = 9.7 Hz, 1H, H-4'), 5.02 (dd, *J* = 9.6, 7.8 Hz, 1H, H-2'), 4.57 (d, *J* = 8.0 Hz, 1H, H-1'), 4.42 (dd, *J* = 12.2, 3.2 Hz, 1H, H-3a), 4.32–4.09 (m, 4H, H-2,3b,6'), 4.03–3.96 (m, 1H, H-1a), 3.81–3.68 (m, 2H, H-1b,5'), 2.39–2.33 (m, 2H, CH<sub>2</sub>), 2.17–2.01 (m, 14H, 4 × OAc, CH<sub>2</sub>), 1.73–1.57 (m, 4H, 2 × CH<sub>2</sub>), 1.39–1.21 (m, 28H, 14 × CH<sub>2</sub>), 0.96–0.86 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.4, 170.8, 170.3, 169.6 (C=O); 100.7 (C-1'), 82.2 (CH), 72.5 (C-3'), 72.1 (C-5'), 71.5 (C-2'), 68.4 (C-4'), 67.9, 61.8, 61.4, 34.2, 33.2, 32.1, 31.5, 29.8, 29.8, 29.6, 29.5, 29.4, 29.2, 25.2, 25.0, 22.8, 22.5 (CH<sub>2</sub>); 20.9, 20.7, 14.3, 14.1 (CH<sub>3</sub>); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>39</sub>H<sub>68</sub>NO<sub>14</sub> 774.4640; found 774.4634.

**(2R)-2-O-Octanoylamino-1-O-palmitoyl-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (14).** From **12** (151 mg, 0.22 mmol) and octanoic acid, compound **14** was obtained as a paste (147 mg, 82%); *R*<sub>f</sub> = 0.62 (petroleum ether/EtOAc 1/1); [α]<sub>D</sub><sup>20</sup> –49.3 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.81 (s, 1H, NH), 5.24 (t, *J* = 9.4 Hz, 1H, H-3'), 5.09 (t, *J* = 9.6 Hz, 1H, H-4'), 5.02 (t, *J* = 8.8 Hz, 1H, H-2'), 4.57 (d, *J* = 7.8 Hz, 1H, H-1'), 4.42 (d, *J* = 10.0 Hz, 1H, H-3a), 4.31–4.09 (m, 4H, H-2,3b,6'), 4.03–3.96 (m, 1H, H-1a), 3.79–3.68 (m, 2H, H-1b,5'), 2.36 (t, *J* = 7.2 Hz, 2H, CH<sub>2</sub>), 2.16–2.00 (m, 14H, 4 × OAc, CH<sub>2</sub>), 1.68–1.58 (m, 4H, 2 × CH<sub>2</sub>), 1.40–1.20 (m, 32H, 16 × CH<sub>2</sub>), 0.93–0.84 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.4, 170.8, 170.4, 170.3, 169.6 (C=O); 100.7 (C-1'), 82.5 (CH), 72.5 (C-3'), 72.1 (C-5'), 71.5 (C-2'), 68.4 (C-4'), 67.9, 61.8, 61.4, 34.2, 33.2, 32.1, 31.8, 29.8, 29.6, 29.5, 29.4, 29.2, 29.1, 25.5, 25.0, 22.8, 22.7 (CH<sub>2</sub>); 20.9, 20.7, 14.3 (CH<sub>3</sub>); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>72</sub>NO<sub>14</sub> 802.4953; found 802.4947.

**(2R)-2-O-(2-Ethylhexanoyl)amino-1-O-palmitoyl-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (15).** From **12** (151 mg, 0.22 mmol) and 2-ethylhexanoic acid, compound **15** was obtained as a paste (114 mg, 64%); *R*<sub>f</sub> = 0.47 (petroleum ether/EtOAc 1/1); [α]<sub>D</sub><sup>20</sup> –38.0 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.87 (s, 1H, NH), 5.25 (t, *J* = 9.4 Hz, 1H, H-3'), 5.09 (t, *J* = 9.7 Hz, 1H, H-4'), 5.01 (t, *J* = 8.7 Hz, 1H, H-2'), 4.57 (d, *J* = 7.7 Hz, 1H, H-1'), 4.47–4.39 (m, 1H, H-3a), 4.31–4.10 (m, 4H, H-2,3b,6'), 4.03–3.96 (m, 1H, H-1a), 3.78–3.69 (m, 2H, H-1b,5'), 2.36 (t, *J* = 7.2 Hz, 2H, CH<sub>2</sub>), 2.10, 2.09, 2.04, 2.02 (4 × s, 12H, 4 × OAc), 1.95–1.85 (m, 1H, CH), 1.69–1.57 (m, 4H, 2 × CH<sub>2</sub>), 1.52–1.39 (m, 2H, CH<sub>2</sub>), 1.37–1.20 (m, 28H, 14 × CH<sub>2</sub>), 0.95–0.84 (m, 9H, 3 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.4, 173.7, 170.8, 170.4, 170.2, 169.6 (C=O); 100.7 (C-1'), 82.2 (CH), 72.5 (C-3'), 72.0 (C-5'), 71.5 (C-2'), 68.3 (C-4'), 67.9, 61.8, 61.3 (CH<sub>2</sub>); 45.7 (CH), 34.3, 34.2, 32.2, 32.0, 29.8, 29.6, 29.5, 29.4, 29.2, 25.9, 24.9, 22.8 (CH<sub>2</sub>); 20.9, 20.8, 20.7, 14.2, 14.1, 12.1 (CH<sub>3</sub>); HRMS (ESI) *m/z* [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>72</sub>NO<sub>14</sub> 802.4953; found 802.4947.

**(2R)-1-O-Palmitoyl-2-O-palmitoylamino-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (16).** From **12** (189 mg, 0.28 mmol) and palmitic acid, compound **15** was obtained as a white solid (192 mg, 76%): mp 74 °C:  $R_f = 0.57$  (petroleum ether/EtOAc 1/1);  $[\alpha]_D -42.3$  (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.86 (s, 1H, NH), 5.24 (t,  $J = 9.5$  Hz, 1H, H-3'), 5.09 (t,  $J = 9.7$  Hz, 1H, H-4'), 5.02 (t,  $J = 9.6$ , 7.8 Hz, 1H, H-2'), 4.57 (d,  $J = 7.9$  Hz, 1H, H-1'), 4.42 (dd,  $J = 12.2$ , 3.3 Hz, 1H, H-3a), 4.32–4.08 (m, 4H, H-2,3b,6'), 4.03–3.96 (m, 1H, H-1a), 3.78–3.69 (m, 2H, H-1b,5'), 2.36 (t,  $J = 7.5$  Hz, 2H, CH<sub>2</sub>), 2.18–2.01 (m, 14H, 4 × OAc, CH<sub>2</sub>), 1.68–1.58 (m, 4H, 2 × CH<sub>2</sub>), 1.40–1.22 (m, 48H, 24 × CH<sub>2</sub>), 0.93–0.81 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.4, 171.2, 170.8, 170.2, 169.5 (C=O); 100.7 (C-1'), 82.1 (CH), 72.5 (C-3'), 72.1 (C-5'), 71.4 (C-2'), 68.4 (C-4'), 67.8, 61.8, 61.3, 34.2, 33.3, 32.0, 29.8, 29.6, 29.5, 29.4, 29.2, 25.5, 24.9, 22.8 (CH<sub>2</sub>); 20.8, 20.7, 14.2 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>88</sub>NO<sub>14</sub> 914.6205; found 914.6199.

**(2R)-2-O-Oleoylamino-1-O-palmitoyl-3-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)glycerol (17).** From **12** (151 mg, 0.22 mmol) and oleic acid, compound **17** was obtained as a white solid (206 mg, 87%): mp 57 °C:  $R_f = 0.52$  (petroleum ether/EtOAc 1/1);  $[\alpha]_D -35.3$  (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.83 (s, 1H, NH), 5.43–5.32 (m, 2H, CH=CH), 5.24 (t,  $J = 9.5$  Hz, 1H, H-3'), 5.09 (t,  $J = 9.7$  Hz, 1H, H-4'), 5.02 (dd,  $J = 9.6$ , 8.0 Hz, 1H, H-2'), 4.57 (d,  $J = 7.9$  Hz, 1H, H-1'), 4.42 (dd,  $J = 12.2$ , 3.3 Hz, 1H, H-3a), 4.32–4.08 (m, 4H, H-2,3b,6'), 4.03–3.96 (m, 1H, H-1a), 3.78–3.69 (m, 2H, H-1b,5'), 2.36 (t,  $J = 7.5$  Hz, 2H, CH<sub>2</sub>), 2.20–1.98 (m, 16H, 4 × OAc, 2 × CH<sub>2</sub>), 1.71–1.57 (m, 4H, 2 × CH<sub>2</sub>), 1.39–1.21 (m, 46H, 23 × CH<sub>2</sub>), 0.95–0.82 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.5, 170.8, 170.4, 170.3, 169.6 (C=O); 130.1, 129.8 (CH=CH); 100.7 (C-1'), 82.2 (CH), 72.5 (C-3'), 72.1 (C-5'), 71.4 (C-2'), 68.4 (C-4'), 67.8, 61.8, 61.3, 34.2, 33.3, 32.0, 29.9, 29.8, 29.6, 29.5, 29.4, 29.2, 27.3, 25.5, 25.0, 22.8 (CH<sub>2</sub>); 20.8, 20.7, 14.3 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>90</sub>NO<sub>14</sub> 940.6361; found 940.6356.

**General Procedure B for Deacetylation. Synthesis of (2R)-2-O-acylamino-3-O-β-D-glucopyranosyl-1-O-palmitoylglycerol (18–22).** To a solution of acetylated compound (0.1 mmol) in 85% EtOH (5 mL) was added N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (1.2 mmol). The mixture was stirred at 50 °C overnight. The solution was poured into ice-cold brine and extracted with CHCl<sub>3</sub> (3 × 20 mL). The combined CHCl<sub>3</sub> layers were dried over MgSO<sub>4</sub>, filtered, evaporated, and purified by column chromatography over silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 30/1 to 20/1).

**(2R)-3-O-β-D-Glucopyranosyl-2-O-hexanoylamino-1-O-palmitoylglycerol (18).** Deacetylation of **13** (105 mg, 0.14 mmol) led to **18** as a white solid (30 mg, 44% yield): mp 94 °C:  $R_f = 0.43$  (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 8/1);  $[\alpha]_D -32.0$  (c 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.35–4.20 (m, 3H, H-1',3), 4.19–4.12 (m, 1H, H-2), 4.04 (dd,  $J = 11.4$ , 3.9 Hz, 1H, H-1a), 3.86 (d,  $J = 11.7$  Hz, 1H, H-6'a), 3.75 (dd,  $J = 11.4$ , 6.1 Hz, 1H, H-1b), 3.67–3.61 (m, 1H, H-6'b), 3.40–3.24 (m, 3H, H-3',4',5'), 3.22–3.15 (m, 1H, H-2'), 2.34 (t,  $J = 7.4$  Hz, 2H, CH<sub>2</sub>), 2.07 (t,  $J = 7.4$  Hz, 2H, CH<sub>2</sub>), 1.70–1.55 (m, 4H, 2 × CH<sub>2</sub>), 1.45–1.22 (m, 28H, 14 × CH<sub>2</sub>), 0.97–0.85 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 175.2, 173.2 (C=O); 104.9 (C-1'), 83.7, 78.0, 77.9, 75.0, 71.6 (CH); 69.0, 63.3, 62.7, 34.9, 33.7, 33.1, 32.4, 30.8, 30.6, 30.5, 30.2, 26.3, 25.9, 23.7, 23.4 (CH<sub>2</sub>); 14.5, 14.3 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>31</sub>H<sub>60</sub>NO<sub>10</sub> 606.4217; found 606.4212.

**(2R)-3-O-β-D-Glucopyranosyl-2-O-octanoylamino-1-O-palmitoylglycerol (19).** Deacetylation of **14** (95 mg, 0.12 mmol) led to **19** as a white solid (35 mg, 47% yield): mp 96 °C:  $R_f = 0.26$  (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 10/1);  $[\alpha]_D -21.7$  (c 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.37–4.19 (m, 3H, H-1',3), 4.19–4.12 (m, 1H, H-2), 4.04 (dd,  $J = 11.4$ , 3.8 Hz, 1H, H-1a), 3.86 (d,  $J = 11.6$  Hz, 1H, H-6'a), 3.75 (dd,  $J = 11.4$ , 6.2 Hz, 1H, H-1b), 3.63 (dd,  $J = 9.8$ , 7.2 Hz, 1H, H-6'b), 3.40–3.24 (m, 3H, H-3',4',5'), 3.22–3.16 (m, 1H, H-2'), 2.34 (t,  $J = 7.4$  Hz, 2H, CH<sub>2</sub>), 2.07 (t,  $J = 7.4$  Hz, 2H, CH<sub>2</sub>), 1.69–1.54 (m, 4H, 2 × CH<sub>2</sub>), 1.48–1.22 (m, 32H, 16 × CH<sub>2</sub>), 1.01–0.81 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 175.2, 173.2 (C=O); 104.9 (C-1'), 83.7, 78.0, 77.9, 75.0, 71.6 (CH); 69.0, 63.3, 62.7,

34.9, 33.8, 33.1, 32.9, 30.8, 30.6, 30.5, 30.2, 30.2, 26.6, 25.9, 23.8, 23.7 (CH<sub>2</sub>); 14.5 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>64</sub>NO<sub>10</sub> 634.4530; found 634.4525.

**(2R)-2-O-(2-Ethylhexanoyl)amino-3-O-β-D-glucopyranosyl-1-O-palmitoylglycerol (20).** Deacetylation of **15** (85 mg, 0.106 mmol) led to **20** as a paste (29 mg, 43% yield):  $R_f = 0.39$  (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 10/1);  $[\alpha]_D -29.7$  (c 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.37–4.21 (m, 3H, H-1',3), 4.20–4.12 (m, 1H, H-2), 4.05 (dd,  $J = 11.1$ , 3.9 Hz, 1H, H-1a), 3.85 (d,  $J = 11.7$  Hz, 1H, H-6'a), 3.75 (dd,  $J = 11.3$ , 6.2 Hz, 1H, H-1b), 3.71–3.60 (m, 1H, H-6'b), 3.44–3.24 (m, 3H, H-3',4',5'), 3.22–3.15 (m, 1H, H-2'), 2.34 (t,  $J = 7.3$  Hz, 2H, CH<sub>2</sub>), 2.03–1.90 (m, 1H, CH), 1.70–1.50 (m, 4H, 2 × CH<sub>2</sub>), 1.49–1.17 (m, 30H, 15 × CH<sub>2</sub>), 1.06–0.81 (m, 9H, 3 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 175.7, 175.2 (C=O); 104.9 (C-1'), 83.9, 78.0, 77.9, 75.0, 71.5 (CH); 69.0, 63.2, 62.7 (CH<sub>2</sub>); 46.6 (CH), 34.8, 33.3, 33.1, 30.8, 30.6, 30.5, 30.2, 26.9, 25.9, 23.7, 23.7 (CH<sub>2</sub>); 14.5, 14.4, 12.4 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>64</sub>NO<sub>10</sub> 634.4530; found 634.4525.

**(2R)-3-O-β-D-Glucopyranosyl-1-O-palmitoyl-2-O-palmitoylaminoglycerol (21).** Deacetylation of **16** (62 mg, 0.068 mmol) led to **21** as a white solid (31 mg, 61% yield): mp 177 °C:  $R_f = 0.24$  (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20/1);  $[\alpha]_D -14.0$  (c 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.39–4.22 (m, 3H, H-1',3), 4.22–4.16 (m, 1H, H-2), 4.08 (dd,  $J = 11.6$ , 3.5 Hz, 1H, H-1a), 3.90 (d,  $J = 12.0$  Hz, 1H, H-6'a), 3.78 (dd,  $J = 11.6$ , 6.3 Hz, 1H, H-1b), 3.69 (dd,  $J = 11.8$ , 5.2 Hz, 1H, H-6'b), 3.43–3.23 (m, 4H, H-2',3',4',5'), 2.37 (t,  $J = 7.5$  Hz, 2H, CH<sub>2</sub>), 2.10 (t,  $J = 7.4$  Hz, 2H, CH<sub>2</sub>), 1.69–1.58 (m, 4H, 2 × CH<sub>2</sub>), 1.49–1.10 (m, 48H, 24 × CH<sub>2</sub>), 0.96–0.86 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 175.1, 172.9 (C=O); 104.6 (C-1'), 83.4, 77.5, 74.6, 71.2 (CH); 68.9, 63.0, 62.5, 34.7, 33.6, 32.8, 30.5, 30.3, 30.2, 30.0, 26.3, 25.6, 23.4 (CH<sub>2</sub>); 14.4 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>80</sub>NO<sub>10</sub> 746.5782; found 746.5777.

**(2R)-3-O-β-D-Glucopyranosyl-2-O-oleoylamino-1-O-palmitoylglycerol (22).** Deacetylation of **17** (125 mg, 0.133 mmol) led to **22** as a white solid (35 mg, 34% yield): mp 162 °C:  $R_f = 0.32$  (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 10/1);  $[\alpha]_D -18.0$  (c 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 5.32 (s, 2H, CH=CH), 4.37–4.20 (m, 3H, H-1',3), 4.19–4.11 (m, 1H, H-2), 4.04 (d,  $J = 10.0$  Hz, 1H, H-1a), 3.85 (d,  $J = 11.3$  Hz, 1H, H-6'a), 3.79–3.71 (m, 1H, H-1b), 3.68–3.58 (m, 1H, H-6'b), 3.40–3.22 (m, 3H, H-3',4',5'), 3.19 (t,  $J = 7.9$  Hz, 1H, H-2'), 2.40–2.28 (m, 2H, CH<sub>2</sub>), 2.14–1.94 (m, 4H, 2 × CH<sub>2</sub>), 1.67–1.52 (m, 4H, 2 × CH<sub>2</sub>), 1.48–1.10 (m, 46H, 23 × CH<sub>2</sub>), 0.97–0.80 (m, 6H, 2 × CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 175.2, 173.2 (C=O); 130.9, 130.8 (CH=CH); 104.9 (C-1'), 83.7, 78.0, 77.9, 75.0, 71.6 (CH); 69.0, 63.4, 62.7, 34.9, 33.8, 33.1, 30.8, 30.7, 30.5, 30.4, 30.2, 28.2, 26.6, 26.0, 23.8 (CH<sub>2</sub>); 14.5 (CH<sub>3</sub>); HRMS (ESI)  $m/z$  [M + H]<sup>+</sup> calcd for C<sub>43</sub>H<sub>82</sub>NO<sub>10</sub> 772.5939; found 772.5933.

## ■ ASSOCIATED CONTENT

### Supporting Information

Copies of <sup>1</sup>H, <sup>13</sup>C, Dept-135, COSY, and HMQC NMR spectra of all described compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: joanne.xie@ppsm.ens-cachan.fr.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

N.C. gratefully acknowledges China Scholarship Council (CSC) for a doctoral scholarship.

## ■ REFERENCES

- (1) Shirahashi, H.; Murakami, N.; Watanabe, M.; Nagatsu, A.; Sakakibara, J.; Tokuda, H.; Nishino, H.; Iwashima, A. *Chem. Pharm. Bull.* **1993**, *41*, 1664–1666.
- (2) (a) Murakami, C.; Kumagai, T.; Hada, T.; Kanekazu, U.; Nakazawa, S.; Kamisuki, S.; Maeda, N.; Xu, X.; Yoshida, H.; Sugawara, F.; Sakaguchi, K.; Mizushima, Y. *Biochem. Pharmacol.* **2003**, *65*, 259–267. (b) Maeda, N.; Hada, T.; Murakami-Nakai, C.; Kuriyama, I.; Ichikawa, H.; Fukumori, Y.; Hiratsuka, J.; Yoshida, H.; Sakaguchi, K.; Mizushima, Y. *J. Nutr. Biochem.* **2005**, *16*, 121–128. (c) Maeda, N.; Matsubara, K.; Yoshida, H.; Mizushima, Y. *Mini-Rev. Med. Chem.* **2011**, *11*, 32–38. (d) Colombo, D.; Scala, A.; Taino, I. M.; Toma, L.; Ronchetti, F.; Tokuda, H.; Nishino, H.; Nagatsu, A.; Sakakibara, J. *Cancer Lett.* **1998**, *123*, 83–86. (e) Sun, Y.; Zhang, J.; Li, C.; Guan, H.; Yu, G. *Carbohydr. Res.* **2012**, *355*, 6–12. (f) Tanaka, R.; Sakano, Y.; Nagatsu, A.; Shibuya, M.; Ebizuka, Y.; Goda, Y. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 159–162.
- (3) Kinjo, Y.; Tupin, E.; Wu, D.; Fujio, M.; Garcia-Navarro, R.; Benhnia, M. R.; Zajonc, D. M.; Ben-Menachem, G.; Ainge, G. D.; Painter, G. F.; Khurana, A.; Hoebe, K.; Behar, S. M.; Beutler, B.; Wilson, I. A.; Tsuji, M.; Sellati, T. J.; Wong, C.-H.; Kronenberg, M. *Nat. Immunol.* **2006**, *7*, 978–986.
- (4) (a) Natori, T.; Morita, M.; Akimoto, K.; Koezuka, Y. *Tetrahedron* **1994**, *50*, 2771–2784. (b) Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Koezuka, Y.; Kobayashi, E.; Fukushima, H. *J. Med. Chem.* **1995**, *38*, 2176–2187.
- (5) (a) Schnaar, R. L.; Suzuki, A.; Stanley, P. In *Essentials of Glycobiology*, 2nd ed.; Varki, A., Cummings, R. D., Esko, J. D., Freeze, H. H., Stanley, P., Bertozzi, C. R., Hart, G. W., Etzler, M. E., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2009; Chapter 10. (b) Schnaar, R. L. *Arch. Biochem. Biophys.* **2004**, *426*, 163–172.
- (6) (a) Long, X.; Deng, S.; Mattner, J.; Zang, Z.; Zhou, D.; McNary, N.; Goff, R. D.; Teyton, L.; Bendelac, A.; Savage, P. B. *Nat. Chem. Biol.* **2007**, *3*, 559–564. (b) Wu, D.; Fujio, M.; Wong, C.-H. *Bioorg. Med. Chem.* **2008**, *16*, 1073–1083.
- (7) Banchet-Cadeddu, A.; Hénon, E.; Dauchez, M.; Renault, J.-H.; Monneaux, F.; Haudrechy, A. *Org. Biomol. Chem.* **2011**, *9*, 3080–3104 and references therein.
- (8) Lee, T.; Cho, M.; Ko, S.-Y.; Youn, H.-J.; Baek, D. J.; Cho, W.-J.; Kang, C.-Y.; Kim, S. *J. Med. Chem.* **2007**, *50*, 585–589.
- (9) Malhotra, R. *Biochem. Anal. Biochem.* **2012**, *1*, 108.
- (10) Li, X.; Wu, Y.-D.; Yang, D. *Acc. Chem. Res.* **2008**, *41*, 1428–1438.
- (11) Chandrasekhar, S.; Rao, C. L.; Reddy, M. S.; Sharma, G. D.; Kiran, M. U.; Naresh, P.; Chaitanya, G. K.; Bhanuprakash, K.; Jagadeesh, B. *J. Org. Chem.* **2008**, *73*, 9443–9446.
- (12) Chen, F.; Ma, B.; Yang, Z.-C.; Lin, G.; Yang, D. *Amino Acids* **2012**, *43*, 499–503.
- (13) (a) Malapelle, A.; Ramozzi, R.; Xie, J. *Synthesis* **2009**, 888–890. (b) Gong, Y. C.; Sun, H. B.; Xie, J. *Eur. J. Org. Chem.* **2009**, 6027–6033. (c) Gong, Y.; Peyrat, S.; Sun, H.; Xie, J. *Tetrahedron* **2011**, *67*, 7114–7120. (d) Song, Z.; He, X.-P.; Chen, G.-R.; Xie, J. *Synthesis* **2011**, 2761–2766. (e) Peyrat, S.; Xie, J. *Synthesis* **2012**, *44*, 1718–1724. (f) Noel, O.; Xie, J. *Synthesis* **2013**, *45*, 134–140. (g) Peyrat, S.; Cheng, K.; Xie, J. *Synthesis* **2013**, *45*, 2737–2744. (h) Zhang, H.-L.; Zang, Y.; Xie, J.; Chen, G.-R.; He, X.-P.; Tian, H. *Sci. Rep.* **2014**, *4*, 5513.
- (14) Ishida, J.; Hinou, H.; Naruchi, K.; Nishimura, S.-I. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 1197–1200.
- (15) van Boeckel, C. A. A.; Visser, G. M.; van Boom, J. H. *Tetrahedron* **1985**, *41*, 4557–4565.
- (16) Yadav, V. K.; Agrawal, D. *Chem. Commun.* **2007**, 5232–5234.
- (17) Mannock, D. A.; Lewis, R. N.; McElhaney, R. N. *Chem. Phys. Lipids* **1987**, *43*, 113–127.
- (18) Janwitayanuchit, W.; Suwanborirux, K.; Patarapanich, C.; Pummangura, S.; Lipipun, V.; Vilaivan, T. *Phytochemistry* **2003**, *64*, 1253–1264.
- (19) Bartoszewicz, A.; Kalek, M.; Stawinski, J. *Tetrahedron* **2008**, *64*, 8843–8850.
- (20) (a) Schenk, S.; Weston, J.; Anders, E. *J. Am. Chem. Soc.* **2005**, *127*, 12566–12576. (b) But, T. Y. S.; Toy, P. H. *Chem.—Asian J.* **2007**, *2*, 1340–1355.